U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H14N4O2.C2H4O2
Molecular Weight 234.2529
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARGININE ACETATE

SMILES

CC(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O

InChI

InChIKey=OZBJWQQAAQSQPL-WCCKRBBISA-N
InChI=1S/C6H14N4O2.C2H4O2/c7-4(5(11)12)2-1-3-10-6(8)9;1-2(3)4/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);1H3,(H,3,4)/t4-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C6H14N4O2
Molecular Weight 174.201
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and as a treatment for erectile dysfunction in men. L-arginine is a nonessential amino acid that may play an important role in the treatment of heart disease due to its block arterial plaque buildup, blood clots, platelet clumping, and to increase blood flow through the coronary artery. L-arginine is commonly sold as a health supplement claiming to improve vascular health and treat erectile dysfunction in men. L-arginine, which is promoted as a human growth stimulant, has also been used in bodybuilding. In the 1800s, it was first isolated from animal horn.

CNS Activity

Curator's Comment: L-Arginine has the ability to cross the blood brain barrier.

Originator

Curator's Comment: Arginine was first isolated from a lupin seedling extract in 1886 by the German chemist Ernst Schultze.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q5T6X5
Gene ID: 222545.0
Gene Symbol: GPRC6A
Target Organism: Homo sapiens (Human)
44.1 µM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

1973
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

1973
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

1973
Diagnostic
R-GENE 10

Approved Use

R-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%.

Launch Date

1973
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
310 μM
6 g single, oral
dose: 6 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
6219 μM
30 g single, intravenous
dose: 30 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
882 μM
6 g single, intravenous
dose: 6 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
24788 M × min
6 g single, oral
dose: 6 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
265435 M × min
30 g single, intravenous
dose: 30 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
38223 M × min
6 g single, intravenous
dose: 6 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
77.5 min
6 g single, oral
dose: 6 g
route of administration: Oral
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
41.6 min
30 g single, intravenous
dose: 30 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
59.6 min
6 g single, intravenous
dose: 6 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ARGININE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
100%
ARGININE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Disc. AE: Cardiopulmonary arrest, Metabolic acidosis...
AEs leading to
discontinuation/dose reduction:
Cardiopulmonary arrest
Metabolic acidosis (acute)
Hyponatremia (severe)
Sources: Page: p.621
200 mg/kg 3 times / day multiple, oral
Highest studied dose
Dose: 200 mg/kg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg/kg, 3 times / day
Sources: Page: p.63
unhealthy, 24
n = 11
Health Status: unhealthy
Condition: Cystic fibrosis
Age Group: 24
Sex: M+F
Population Size: 11
Sources: Page: p.63
15 g 2 times / day multiple, oral
Studied dose
Dose: 15 g, 2 times / day
Route: oral
Route: multiple
Dose: 15 g, 2 times / day
Sources: Page: p.1
healthy, 34 ± 2.6
n = 12
Health Status: healthy
Condition: Dietary supplementation
Age Group: 34 ± 2.6
Sex: M+F
Population Size: 12
Sources: Page: p.1
7 g 3 times / day multiple, oral
Studied dose
Dose: 7 g, 3 times / day
Route: oral
Route: multiple
Dose: 7 g, 3 times / day
Sources: Page: p.200
unhealthy, 43± 16
n = 10
Health Status: unhealthy
Condition: Hypercholesterolaemia
Age Group: 43± 16
Sex: M+F
Population Size: 10
Sources: Page: p.200
DLT: Gastrointestinal discomfort...
Dose limiting toxicities:
Gastrointestinal discomfort (20%)
Sources: Page: p.200
AEs

AEs

AESignificanceDosePopulation
Cardiopulmonary arrest Disc. AE
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Metabolic acidosis acute
Disc. AE
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Hyponatremia severe
Disc. AE
3.9 g/kg single, intravenous
Accidental dose
Dose: 3.9 g/kg
Route: intravenous
Route: single
Dose: 3.9 g/kg
Sources: Page: p.621
unhealthy, 1.75
n = 1
Health Status: unhealthy
Condition: Short stature
Age Group: 1.75
Sex: F
Population Size: 1
Sources: Page: p.621
Gastrointestinal discomfort 20%
DLT
7 g 3 times / day multiple, oral
Studied dose
Dose: 7 g, 3 times / day
Route: oral
Route: multiple
Dose: 7 g, 3 times / day
Sources: Page: p.200
unhealthy, 43± 16
n = 10
Health Status: unhealthy
Condition: Hypercholesterolaemia
Age Group: 43± 16
Sex: M+F
Population Size: 10
Sources: Page: p.200
PubMed

PubMed

TitleDatePubMed
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies.
2001
The dialytic failure of the peritoneal membrane.
2001
Protein traffic in bacteria: multiple routes from the ribosome to and across the membrane.
2001
Nucleocytoplasmic shuttling of heterodimeric splicing factor U2AF.
2001 Apr 20
Dose response of arginine vasopressin to the CCK-B agonist pentagastrin.
2001 Feb
Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain.
2001 Feb 2
Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of the catalytic activity of glutathione transferases.
2001 Feb 23
Current strategies for the management of neonatal urea cycle disorders.
2001 Jan
Biglycan, a vascular proteoglycan, binds differently to HDL2 and HDL3: role of apoE.
2001 Jan
Regulation of potassium channel Kir 1.1 (ROMK) abundance in the thick ascending limb of Henle's loop.
2001 Jan
Increased colocalization of corticotropin-releasing factor and arginine vasopressin in paraventricular neurones of the hypothalamus in lactating rats: evidence from immunotargeted lesions and immunohistochemistry.
2001 Jan
Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension.
2001 Jan
In vitro studies of a prolactin antagonist, hPRL-G129R in human breast cancer cells.
2001 Jan
Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70.
2001 Jan 1
Specific interactions at the regulatory domain-substrate binding domain interface influence the cooperativity of inhibition and effector binding in Escherichia coli D-3-phosphoglycerate dehydrogenase.
2001 Jan 12
Glutamine metabolism to glucosamine is necessary for glutamine inhibition of endothelial nitric oxide synthesis.
2001 Jan 15
Strain is more important than electrostatic interaction in controlling the pKa of the catalytic group in aspartate aminotransferase.
2001 Jan 16
A proposed common structure of substrates bound to mitochondrial processing peptidase.
2001 Jan 19
The role of nitric oxide in bradycardia of rats with obstructive cholestasis.
2001 Jan 5
L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin.
2001 Jan 5
A single arginyl residue in plastocyanin and in cytochrome c(6) from the cyanobacterium Anabaena sp. PCC 7119 is required for efficient reduction of photosystem I.
2001 Jan 5
Identification and analysis of the acyl carrier protein (ACP) docking site on beta-ketoacyl-ACP synthase III.
2001 Mar 16
A single histidine residue determines the pH sensitivity of the pacemaker channel HCN2.
2001 Mar 2
Scanning mutagenesis reveals roles for helix n of the bacteriophage T7 RNA polymerase thumb subdomain in transcription complex stability, pausing, and termination.
2001 Mar 30
Identification of the collagen-binding site of the von Willebrand factor A3-domain.
2001 Mar 30
The modulation of oxygen radical production by nitric oxide in mitochondria.
2001 Mar 9
Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R.
2001 Mar 9
Increased production of human proinsulin in the periplasmic space of Escherichia coli by fusion to DsbA.
2001 Nov 30
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: I.V route is possible: The recommended adult dose is 30 g arginine hydrochloride (300 mL of R-Gene 10) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g arginine hydrochloride. https://www.drugs.com/dosage/r-gene-10.html
L-arginine has been studied at oral doses of 6 to 30 g/day for a variety of conditions. Many formulations have been used.
Route of Administration: Oral
A strong inward current in X. laevis oocytes expressing 5.24 (C terminus of the homologous goldfish 5.24 receptor) when L-Arg (L-arginine) was applied at 10 uM. When testing chimera h6A/5.24 (h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor) in this system, the responses were obtained with L-Arg at 100 uM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:13:32 GMT 2023
Edited
by admin
on Fri Dec 15 15:13:32 GMT 2023
Record UNII
4IMS9I1TBW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ARGININE ACETATE
Common Name English
L-ARGININE, MONOACETATE
Systematic Name English
L-ARGININE, ACETATE (1:1)
Systematic Name English
Arginine acetate [WHO-DD]
Common Name English
Code System Code Type Description
PUBCHEM
172746
Created by admin on Fri Dec 15 15:13:32 GMT 2023 , Edited by admin on Fri Dec 15 15:13:32 GMT 2023
PRIMARY
CAS
71173-62-1
Created by admin on Fri Dec 15 15:13:32 GMT 2023 , Edited by admin on Fri Dec 15 15:13:32 GMT 2023
PRIMARY
EPA CompTox
DTXSID1072268
Created by admin on Fri Dec 15 15:13:32 GMT 2023 , Edited by admin on Fri Dec 15 15:13:32 GMT 2023
PRIMARY
FDA UNII
4IMS9I1TBW
Created by admin on Fri Dec 15 15:13:32 GMT 2023 , Edited by admin on Fri Dec 15 15:13:32 GMT 2023
PRIMARY
ECHA (EC/EINECS)
275-247-2
Created by admin on Fri Dec 15 15:13:32 GMT 2023 , Edited by admin on Fri Dec 15 15:13:32 GMT 2023
PRIMARY
SMS_ID
300000028252
Created by admin on Fri Dec 15 15:13:32 GMT 2023 , Edited by admin on Fri Dec 15 15:13:32 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE